“We are grateful to all the people at the trial sites in the UnitedStates and in the PMS community who have enabled this GROUND BREAKING TRIAL to be completed as westrive to develop a potential first therapy for PMS. We look forward to releasing next month the firstresults of treatment with NNZ-2591 in children with PMS.”
If the bold lettering doesn’t scream “breakthrough designation” potential I don’t know what will. Remember, this is open label. My word this really gets my Johnson going.
Ann: Neuren completes Phelan-McDermid syndrome Phase 2 trial, page-5
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$19.29 |
Change
-0.980(4.83%) |
Mkt cap ! $2.473B | |||
| Open | High | Low | Value | Volume |
| $20.40 | $20.50 | $18.92 | $9.975M | 511.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 317 | $19.27 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $19.29 | 500 | 9 |
View Market Depth
| Last trade - 13.23pm 04/06/2024 (20 minute delay) ? |
|
|||||
|
Last
$19.14 |
Change
-0.980 ( 6.00 %) |
||||
| Open | High | Low | Volume | ||
| $20.39 | $20.46 | $18.92 | 192189 | ||
| Last updated 13.42pm 04/06/2024 ? | |||||
| NEU (ASX) Chart |